PFE sold the DRTX drug AFTER running P3 trials that were not suitable for registration. That is certainly a red flag.
Also, it is hard to find much on the AE profile. All I see in the printed stuff is "as expected", but that could still be worse than vanomycin etc. And with a longer PK/PD profile any AEs could be exaggerated.
CHTP is flying, I have a small position compared to my TSRX position. I got CHTP when nobody cared for $1.8X; 39,000 shares not too long ago. LOL, that beats DRTX and I am up double on TSRX. BOOM ON; DRTX and all of them could go much higher, Small pharma/bios are hot!!